Analysts at Leerink Swann started coverage on shares of Transcept Pharmaceuticals Incorporated (NASDAQ: TSPT) in a research report issued to clients and investors on Monday. The firm set an “outperform” rating on the stock.
A number of other analysts have also recently weighed in on TSPT. Analysts at Cowen initiated coverage on shares of Transcept Pharmaceuticals Incorporated in a research note to investors on Tuesday, May 15th. They set an “outperform” rating on the stock. Analysts at MLV & Co raised their price target on shares of Transcept Pharmaceuticals Incorporated from $21.00 to $24.00 in a research note to investors on Monday, March 26th.
Transcept Pharmaceuticals Incorporated traded down 0.75% on Monday, hitting $6.60. Transcept Pharmaceuticals Incorporated has a 1-year low of $2.58 and a 1-year high of $12.99. The company’s market cap is $122.4 million.
Transcept Pharmaceuticals, Inc., formerly Novacea, Inc., is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in neuroscience.